No Data
Express News | Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $87
Crinetics Announces FDA Acceptance of NDA for Paltusotine
Express News | Crinetics Pharmaceuticals Inc - FDA Targets Pdufa Date Sept 25, 2025 for Nda Review Completion
Express News | Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients With Acromegaly